Amgen Inc AMGN
News
-
Amgen Down Nearly 7%, On Pace For Largest Percent Decrease Since March 2020 — Data Talk
-
Beneath the surface, the next stock-market leaders are getting ready to break out, says Morgan Stanley
-
Why the Dow is being dragged down by a Swiss company's bad news
-
FTC Challenges Amgen's Patent Play in Enbrel Antitrust Case
-
Moderna's cancer-vaccine breakthrough drives broad biopharma stock rally
-
Amgen Lifts Outlook on Strong 2Q Drug Sales, to End Early Development of Obesity Treatment
-
European Regulator Calls for Amgen's Tavneos to Have Authorization Revoked
-
Kissei Revises Package Insert in Japan for Amgen's Tavneos
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- CLP 274,700.00–333,290.00
- Bid/Ask
- — / —
- Shares Outstanding
- 540.63M
- Market Cap
- —
- Volume/Avg
- — / 1
Key Statistics
- Price/Earnings (Normalized)
- 15.06
- Price/Sales
- 4.85
- Dividend Yield (Trailing)
- 2.94%
- Dividend Yield (Forward)
- 3.03%
- Dividend Payment Schedule
- Mar, Jun, Sep, Dec
- Total Yield
- 2.94%
Company Profile
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis, which has been further strengthened with the launch of new drugs in blood cancers (Blincyto) and solid tumors (Imdelltra). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Large Value
- Total Number of Employees
- 31,500
- Website
- https://www.amgen.com
Competitors
Valuation
|
Metric
|
AMGN
|
NVS
|
REGN
|
|---|---|---|---|
Price/Earnings (Normalized) | 15.06 | 13.83 | 15.87 |
Price/Book Value | 19.54 | 6.58 | 2.43 |
Price/Sales | 4.85 | 4.89 | 5.14 |
Price/Cash Flow | 14.52 | 14.43 | 17.14 |
Price/Earnings
AMGN
NVS
REGN
Financial Strength
|
Metric
|
AMGN
|
NVS
|
REGN
|
|---|---|---|---|
Quick Ratio | 0.95 | 0.55 | 2.63 |
Current Ratio | 1.37 | 0.86 | 3.34 |
Interest Coverage | 4.86 | 11.90 | 80.98 |
Quick Ratio
AMGN
NVS
REGN
Profitability
|
Metric
|
AMGN
|
NVS
|
REGN
|
|---|---|---|---|
Return on Assets (Normalized) | 13.30% | 14.74% | 12.70% |
Return on Equity (Normalized) | 130.43% | 39.06% | 16.48% |
Return on Invested Capital (Normalized) | 22.07% | 21.25% | 13.47% |
Return on Assets
AMGN
NVS
REGN
Drug Manufacturers - General Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| LOCK|Lm!sxHq | LOCK|<? | $1T | |||
| Johnson & Johnson
JNJ
| LOCK|^xwtrH | LOCK|?n< | $630B | |||
| AbbVie Inc
ABBV
| LOCK|l@#rXPC | LOCK|Wm# | $489B | |||
| Merck & Co Inc
MRK
| LOCK|gkDMD?! | LOCK|W%b | $359B | |||
| Roche Holding AG ADR
RHHBY
| LOCK|Xxml@XJ! | LOCK|BS | $344B | |||
| Novartis AG ADR
NVS
| LOCK|X!!H%m&q | LOCK|Qh | $272B | |||
| AstraZeneca PLC
AZN
| LOCK|&Wbw@%g | LOCK|!Q | $246B | |||
| Amgen Inc
AMGN
| LOCK|L<%T$!$t | LOCK|$bs | $224B | |||
| Gilead Sciences Inc
GILD
| LOCK|B%K<Pj | LOCK|gQy | $187B | |||
| Novo Nordisk AS ADR
NVO
| LOCK|<vx<lL# | LOCK|#Yb | $169B |
United States